Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8713 - 8720 of 11368 results
Regulation A+ goes effective today
June 19, 2015| Blog| Viewpoint
Crowdfunding and IP in Health and Biotech Start-ups (Part 1): The Beginning
June 18, 2015| Blog| Viewpoint
Government Announces Health Care Fraud “Takedown”
June 18, 2015| Blog| Viewpoint
UPDATE: Vivendi Employs Creative Arguments on Damages and the Fraud-on-the-Market Theory to Prevent Class Recovery
June 18, 2015| Blog| Viewpoint
Obama Administration and Private Partners Make a Clean Energy Push
June 17, 2015| Blog| Viewpoint
New Hampshire Establishes Privacy Protections for Student Online Personal Information
June 17, 2015| Blog| Viewpoint
PTAB Grants Fourth Motion to Amend in an IPR Proceeding
June 16, 2015| Blog| Viewpoint
News & Press Releases
Mintz is pleased to announce that Member and Chair of the firm’s Intellectual Property Division Michael Renaud and Members Matthew Galica, Frank Gerratana, Marguerite McConihe, Michael Newman, Adam Rizk, and James Wodarski have been named to the 2024 IAM Strategy 300: The World’s Leading IP Strategists list.
Medicare Drug Price Cuts Add Fuel to Legal Fight Over Program
August 16, 2024
Member Rachel Alexander was quoted in a recent Bloomberg Law article about Medicare drug price cuts and what they might mean for ongoing litigation. Rachel addresses the potential implications of the US government’s release Thursday of the first ten drug prices that were negotiated for Medicare.
Seven Mintz attorneys were recognized in Benchmark Litigation’s 2024 “40 & Under List” which spotlights the “top emerging talent in litigation” who are 40 years old and under. The annual “40 & Under List” is compiled through peer and client review, as well as consideration of individual cases.